申请人:Nanjing Transthera Biosciences Co., Ltd.
公开号:EP3741752A1
公开(公告)日:2020-11-25
The present invention provides a novel inhibitor compound of general formula (I), exhibiting excellent kinase inhibitory activity. The compound of the present invention can be used to prevent and/or treat diseases mediated by abnormal expression of TAM family kinase receptors and/or ligands thereof. In addition, the compound of the present invention can also target CSF1R kinase, and thus can be used to prevent and/or treat diseases mediated by abnormal expression of TAM family kinase receptors and/or CSF1R kinase receptors and/or ligands thereof.
本发明提供了一种通式(I)的新型抑制剂化合物,具有优异的激酶抑制活性。本发明化合物可用于预防和/或治疗由 TAM 家族激酶受体和/或其配体异常表达介导的疾病。此外,本发明化合物还可以靶向 CSF1R 激酶,因此可用于预防和/或治疗由 TAM 家族激酶受体和/或 CSF1R 激酶受体和/或其配体异常表达介导的疾病。